Newsroom | 4306 results

TORONTO--(BUSINESS WIRE)--Give Back Health Innovation Foundation (Give Back), a Canadian philanthropic network advancing public health through innovation and technology, today announced its inaugural partnership with Inteligex, a Canadian company that is working to restore lost function for people living with spinal cord injuries (SCI). According to the Journal of Spinal Cord Medicine, there are about 3,600 new spinal cord injuries in Canada every year, and 86,000 Canadians live with the condit...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) clearance of the clinical trial authorization (CTA) application for its lead program EN-374, an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for the treatment of X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder...

LOS ANGELES--(BUSINESS WIRE)--City of Hope® CEO Robert Stone, who leads one of the largest and most advanced cancer research and treatment organizations in the United States, has been recognized as one of the most influential leaders by two top health care trade publications: Modern Healthcare and Becker’s Hospital Review. Stone was honored for expanding access to advanced cancer care nationwide, advancing breakthrough cancer research, and developing a national network of lifesaving clinical tr...

PARIS--(BUSINESS WIRE)--The first patients in the world have been treated with Scarcell Therapeutics' aGF Therapy using gum cells designed to relieve knee osteoarthritis....

PARIS--(BUSINESS WIRE)--Scarcell Therapeutics, société innovante en thérapie cellulaire destinée aux traitements des maladies inflammatoires chroniques et dégénératives, a annoncé aujourd’hui le traitement des premiers patients au monde avec son produit de thérapie cellulaire aGF à base de fibroblastes gingivaux allogéniques : les cellules de la gencive proviennent d’un donneur humain sont évaluées dans son essai clinique de phase Ib portant sur l’arthrose du genou. Les premières interventions...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based Cellgorithm™ technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today. In traditional cell differentiation, scientists expose stem cells to a serie...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio today announced new data presented on its lead investigational allogeneic T-cell immunotherapy, Orca-T, at the 67th ASH Annual Meeting....

MINNEAPOLIS--(BUSINESS WIRE)--New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., demonstrates that patients receiving allogeneic transplantation using more deeply mismatched unrelated donors (MMUD), followed by post-transplant chemotherapy, can achieve outcomes comparable to those receiving tran...

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health will present new clinical outcomes data at ASH 2025, highlighting the potential of organ donor bone marrow as a promising graft source....